Advanced Micro Devices stock had a terrible run on the market in 2024, losing almost 21% of its value, while the broader PHLX Semiconductor Sector index clocked healthy gains of 24% during this period. This is evident from the 141% gains clocked by AMD during this period as compared to the 170% jump in the PHLX Semiconductor Sector index in the last five years. The weakness in the personal computer market following the novel coronavirus pandemic, the soft demand for gaming consoles, and the chipmaker's failure to jump onto the artificial intelligence (AI) bandwagon while rival Nvidia ran away with this market have all contributed toward AMD's underperformance.
Furthermore, investing in just one AI stock also isn't a great move, as putting all your eggs in one basket is an easy way to miss out on a trend as massive as AI if the pick fails. What this one pick boils down to is my favorite AI stock, which is the one I will add to first if the market suddenly drops. If I had to only own one, I'd likely choose Nvidia (NASDAQ: NVDA).
Niccol, the former Chipotle Mexican Grill head, who is four months into his new role at Starbucks has set forth a raft of measures to improve the coffee chain's business, which took a hit from increased competition and weakening demand in the U.S. and China. "Our size and structure can slow us down, with too many layers, managers of small teams and roles focused primarily on coordinating work," Niccol said in a statement, adding that he will examine the role, structure and size of support teams globally.
The US Department of Justice (DOJ) has filed a lawsuit against Walgreens (WBA), one of the nation's largest pharmacy chains, alleging widespread prescription drug practice violations. According to the DOJ, Walgreens improperly dispensed millions of prescriptions from August 2012 to the present day that either lacked "legitimate medical purpose" or were otherwise invalid. Yahoo Finance anchors Josh Lipton and Alexandra Canal dive into the details, discussing the fines the pharmacy giant would face if found liable — up to $80,850 per unlawful prescription. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith